Octreotide is indicated for the management of conditions associated with excessive hormone secretion, including acromegaly, neuroendocrine tumors (such as carcinoid tumors), and acute control of bleeding from esophageal varices. Its key advantage is potent inhibition of multiple hormones, especially growth hormone, glucagon, and serotonin, leading to rapid symptom control. In emergency and ICU settings, octreotide is particularly valuable for rapid reduction of portal hypertension and control of variceal bleeding, improving patient stability and outcomes. It also reduces gastrointestinal secretions and motility, making it useful in managing secretory diarrhea and complications related to tumors. Intravenous or subcutaneous administration ensures fast onset and reliable effect. Its targeted mechanism and broad clinical utility make octreotide an essential therapy in endocrinology, gastroenterology, and critical care.